A Phase 3 Trial of Inhaled Mosliciguat in PH-ILD (PHrontier)
A Phase 3, Multicenter, Randomized, Double-Blind Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Mosliciguat in Participants with Pulmonary Hypertension Associated with Interstitial Lung Disease
Participants willing and able to provide informed consent. [+5]
Diagnosis of PH Group 1 (eg, pulmonary arterial hypertension), Group 2 (related... [+5]